Actively Recruiting
Randomized Phase IIIII Trial of AK104 or Placebo with Chemotherapy for Adults with Recurrent or Metastatic Nasopharyngeal Carcinoma After First-line Treatment
Led by Sun Yat-sen University · Updated on 2024-02-05
300
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
The trial investigates treatment options for patients with recurrent or metastatic nasopharyngeal carcinoma who have not responded to first-line therapies. Researchers aim to compare the survival benefits, safety, and tolerability of AK104 combined with two chemotherapy regimens, GP or PFLL, against similar chemotherapy regimens combined with a placebo. This Phase IIIII study is designed to evaluate how these combinations perform regarding progression-free survival over 24 months. Participants receive either AK104 or a placebo through intravenous infusion at a dose of 6 mgkg over more than 60 minutes. The study includes four groups based on prior treatment exposure, with chemotherapy regimens consisting of 5-Fu and Cisplatin or Gemcitabine and Cisplatin administered in cycles every three weeks for up to six cycles. AK104 or placebo infusions are given on specific days within each cycle, followed by maintenance doses every two weeks after chemotherapy. During the trial, participants undergo regular assessments including imaging to measure tumor response according to RECIST1.1 criteria, and evaluations of vital organ function and overall health status. Tissue samples collected within three years prior to enrollment are required. Researchers will monitor progression-free survival as the primary outcome and track safety and tolerability throughout the study, which lasts until at least 24 months after treatment begins.
CONDITIONS
Brief Title
A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here